Evidence map›Paper›PMID 39201279›Full record

ReviewInternational journal of molecular sciences2024

Epigenetics, Microbiome and Personalized Medicine: Focus on Kidney Disease.

Giuseppe Gigliotti, Rashmi Joshi, Anam Khalid, David Widmer, Mariarosaria Boccellino, Davide Viggiano

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giuseppe GigliottiDepartment Nephrology and Dialysis, Eboli Hospital, 84025 Eboli, Italy.
Rashmi JoshiDepartment Translational Medical Sciences, University of Campania, 81100 Naples, Italy.ORCID 0000-0001-6065-2594
Anam KhalidDepartment Translational Medical Sciences, University of Campania, 81100 Naples, Italy.
David WidmerVidmar-Daj Consulting, New York, NY 07093, USA.
Mariarosaria BoccellinoDepartment Experimental Medicine, University of Campania, 81100 Naples, Italy.ORCID 0000-0001-6989-010X
Davide ViggianoDepartment Translational Medical Sciences, University of Campania, 81100 Naples, Italy.ORCID 0000-0002-2425-6057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized medicine, which involves modifying treatment strategies/drug dosages based on massive laboratory/imaging data, faces large statistical and study design problems. The authors believe that the use of continuous multidimensional data, such as those regarding gut microbiota, or binary multidimensional systems properly transformed into a continuous variable, such as the epigenetic clock, offer an advantageous scenario for the design of trials of personalized medicine. We will discuss examples focusing on kidney diseases, specifically on IgA nephropathy. While gut dysbiosis can provide a treatment strategy to restore the standard gut microbiota using probiotics, transforming epigenetic omics data into epigenetic clocks offers a promising tool for personalized acute and chronic kidney disease care. Epigenetic clocks involve a complex transformation of DNA methylome data into estimated biological age. These clocks can identify people at high risk of developing kidney problems even before symptoms appear. Some of the effects of both the epigenetic clock and microbiota on kidney diseases seem to be mediated by endothelial dysfunction. These "big data" (epigenetic clocks and microbiota) can help tailor treatment plans by pinpointing patients likely to experience rapid declines or those who might not need overly aggressive therapies.

Indexed as

Epigenesis, GeneticGastrointestinal MicrobiomeKidney DiseasesPrecision MedicineAnimalsDNA MethylationDysbiosisEpigenomicsHumansMicrobiotaepigenomeIgANmicrobiome

Identifiers

PMID39201279
PMCPMC11354516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.